SOURCE: Morria Biopharmaceuticals Plc

Morria Biopharmaceuticals Plc

July 18, 2012 10:00 ET

Morria Biopharmaceuticals Plc Appoints Charles Serhan Ph.D. to Scientific Advisory Board

LONDON and NEW YORK, NY--(Marketwire - Jul 18, 2012) -  Morria Biopharmaceuticals Plc., a biopharmaceutical company focused on developing novel, first-in-class, synthetic, non-steroidal anti-inflammatory drugs, announced today that it has appointed Charles Serhan Ph.D. to its Scientific Advisory Board (SAB). Professor Serhan is internationally acknowledged as a leading authority in the field of inflammation and will bring to Morria outstanding academic achievements and impressive experience in the biopharmaceutical field.

Sir Marc Feldmann, Head of the Kennedy Institute of Rheumatology at the University of Oxford, and a member of Morria's Scientific Advisory Board stated: "It is a pleasure to have Professor Charlie Serhan join Morria's Scientific Advisory Board. His strong scientific background will provide complementary skills to the existing SAB members' expertise, and will augment the development capacity of Morria."

Professor Serhan stated, "I'm very pleased to join the team of international experts at Morria with the goal of bringing new and innovative therapies to the market."

Professor Serhan will be joining a Scientific Advisory Board that includes Sir Marc Feldmann; Professor Peter J. Barnes, Professor of Thoracic Medicine and Head of Airway Disease at the National Heart and Lung Institute of Imperial College (London); and Professor Roderick Flower, Head of Biochemical Pharmacology at the William Harvey Research Institute, Queen Mary's College (London).

Charles N. Serhan is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School and Professor of Oral Medicine, Infection and Immunity at HSDM, Harvard University. Since 1995, he has been the Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women's Hospital in Boston. Professor Serhan received his Bachelor's degree in biochemistry from Stony Brook University, New York, and went on to receive his doctorate in experimental pathology and medical sciences from New York University (NYU) School of Medicine. From 1981-86, he was a visiting scientist at the Karolinska Institutet and post-doctoral fellow with Professor Bengt Samuelsson. In 1996, he received an honorary degree from Harvard University.

Professor Serhan's research interests include the structural elucidation of novel mediators in the resolution of acute inflammation and reperfusion injury and their impact in human disease. Recent studies focus on mechanisms in the resolution of inflammation and receptors for pro-resolving mediators. His discoveries include aspirin-triggered lipid mediators, the resolvins and protectins, and most recently the maresins and their roles in programmed resolution and homeostasis.

Professor Serhan is a member of several societies and editorial boards, including the ASBMB, Inflammation (Associate Editor), American Society for Pharmacology and Experimental Therapeutics, AAI, ASIP and the Journal of Experimental Medicine (Editorial Board). Since 2007 he has served on the Foundation for the NIH Biomarkers Consortium. Professor Serhan led, as principal director, the NIH Program Project Molecular Mechanisms in Leukocyte-Mediated Tissue Injury, and recently served as Principal Investigator/Program Director of the Center grant entitled Specialized Center for Oral Inflammation and Resolution. 

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel, first-in-class, non-steroidal, anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs. This class of drugs targets the soluble phospholipase A2 (sPLA2) enzyme family, a sought-after anti-inflammatory drug target. Morria's mission is to become a pivotal player in the anti-inflammatory drug market by developing and commercializing novel drugs for allergy, respiratory, dermatology, ophthalmological, pulmonary, and gastro-intestinal inflammatory diseases. Morria's lead two drugs (MRX4 in allergic rhinitis and MRX6 in dermatitis) have each demonstrated proof of concept in Phase IIa trials. For more information, please visit:

This press release contains "forward-looking statements" that involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," "hope," "look forward" and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should not put undue reliance on any forward-looking statements. Unless we are required to do so under applicable laws, we do not intend to update or revise any forward-looking statements.

Contact Information